Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY2090314
Drug: pemetrexed
Drug: Carboplatin
Other: ranitidine

First Posted Date: 2011-02-01

Last Posted Date: 2019-02-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT01287520

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Phase 3

Completed

Conditions: Lung Cancer - Non Small Cell Squamous

Interventions: Drug: Placebo
Drug: Ipilimumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2011-01-28

Last Posted Date: 2020-06-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1289

Registration Number: NCT01285609

Locations: 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸
St. Francis Hospital & Health Centers, Indianapolis, Indiana, United States
🇺🇸
Durham Va Medical Center (111g), Durham, North Carolina, United States

and more 31 locations

A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Cancer of the Head and Neck
Head and Neck Neoplasms

Interventions: Drug: Carboplatin
Drug: Cetuximab
Drug: RAD001

First Posted Date: 2011-01-25

Last Posted Date: 2014-12-04

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT01283334

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: everolimus
Drug: carboplatin
Drug: pegylated liposomal doxorubicin hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2011-01-24

Last Posted Date: 2019-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT01281514

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Adult Solid Neoplasm
Estrogen Receptor Negative
Estrogen Receptor Positive
HER2/Neu Negative
Male Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2011-01-21

Last Posted Date: 2015-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT01281150

Locations: 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Adult Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Carboplatin
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Vorinostat

First Posted Date: 2011-01-21

Last Posted Date: 2024-10-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT01281176

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Ductal Adenocarcinoma
Pancreatic Acinar Cell Carcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Biological: Wild-type Reovirus

First Posted Date: 2011-01-20

Last Posted Date: 2018-03-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 73

Registration Number: NCT01280058

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 3 locations

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Not Applicable

Terminated

Conditions: Stage IIC Ovarian Cancer
Stage IIIC Fallopian Tube Cancer
Stage IV Ovarian Cancer
Nausea and Vomiting
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Stage IIB Fallopian Tube Cancer
Stage IIIA Fallopian Tube Cancer
Stage IIA Ovarian Cancer
Stage IIIB Ovarian Cancer

Interventions: Procedure: Adjuvant Therapy
Drug: Aprepitant
Drug: Carboplatin
Drug: Cisplatin
Drug: Dexamethasone
Drug: Granisetron Transdermal Patch
Procedure: Management of Therapy Complications
Other: Questionnaire Administration

First Posted Date: 2011-01-12

Last Posted Date: 2018-05-22

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 4

Registration Number: NCT01275664

Locations: 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸
Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States